NDA 021087 · Roche
Tamiflu
Oseltamivir Phosphate · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Aug 2, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Oct 27, 1999
Approved uses
7
Original approval plus efficacy supplements
Registered trials
156
44 Phase 3, 10 recruiting
FAERS reports
18,140
11,193 serious, 1,814 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 15, 2025.
TAMIFLU is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) 1.1 Treatment of Influenza TAMIFLU is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. 1.2 Prophylaxis of Influenza TAMIFLU is indicated for the prophylaxis of influenza A and B in patients 1 year and older. 1.3 Limitations of Use TAMIFLU is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use TAMIFLU [see Microbiology (12.4) ] . TAMIFLU is not recommended for patients with end-stage renal disease not undergoing dialysis [see Dosage and Administration (2.4) and Use in Specific Populations (8.6) ].
Mechanism: Oseltamivir is an antiviral drug with activity against influenza virus [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 2, 2019 Supplement 71 · Efficacy LabelLetter
- Dec 21, 2012 Supplement 62 · Efficacy · priority review Summary ReviewLetterReview
- Feb 22, 2010 Supplement 49 · Efficacy · priority review ReviewLabelLetter
- Dec 21, 2005 Supplement 30 · Efficacy LetterReviewLabel
- Feb 14, 2003 Supplement 14 · Efficacy · priority review Letter
- Nov 17, 2000 Supplement 2 · Efficacy · priority review LetterReviewLabel
- Oct 27, 1999 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewOther Important Information from FDA
3 products under this application
- TAMIFLU · OSELTAMIVIR PHOSPHATE EQ 30MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
- TAMIFLU · OSELTAMIVIR PHOSPHATE EQ 75MG BASE · CAPSULE, ORAL · Prescription · TE AB
- TAMIFLU · OSELTAMIVIR PHOSPHATE EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Oseltamivir" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05648448 · 3,000 participants (planned) · Start Feb 22, 2023 · Primary completion Jan 1, 2027
Drug: Oseltamivir; Favipiravir and 8 more · For: Influenza; Influenza, Human
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 4 sites in all
- Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza ComplicationsPivotal-lookingCompleted
ShionogiIndustry
NCT02949011 · 2,184 participants · Start Jan 11, 2017 · Primary completion Apr 12, 2018
Drug: Baloxavir Marboxil; Placebo to Baloxavir Marboxil and 2 more · For: Influenza
- Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated InfluenzaPivotal-lookingCompleted
Romark Laboratories L.C.Industry
NCT01610245 · 1,941 participants · Start Mar 2013 · Primary completion Mar 2015
Drug: Nitazoxanide; Oseltamivir and 2 more · For: Influenza
Sites: Birmingham, Alabama; Dothan, Alabama; Hoover, Alabama · 167 sites in all
- A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With InfluenzaPivotal-lookingCompleted
ShionogiIndustry
NCT02954354 · 1,436 participants · Start Dec 8, 2016 · Primary completion Apr 4, 2017
Drug: Baloxavir Marboxil; Placebo to Baloxavir Marboxil and 2 more · For: Influenza
- Oseltamivir Randomised Controlled Efficacy TrialPivotal-lookingCompleted
International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
NCT00707941 · 1,190 participants · Start May 2008 · Primary completion Mar 2011
Drug: Oseltamivir; Placebo · For: Influenza; Pneumonia; Lower Respiratory Tract Infection and 2 more
Sites: Dhaka, Bangladesh
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting1,886
- nausea1,364
- no adverse event1,058
- influenza963
- abnormal behaviour927
- diarrhoea867
- dyspnoea863
- hallucination827
- pyrexia746
- headache678
- drug ineffective648
- pneumonia644
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 153 |
| 2005 | 393 |
| 2006 | 278 |
| 2007 | 546 |
| 2008 | 351 |
| 2009 | 1,569 |
| 2010 | 1,311 |
| 2011 | 477 |
| 2012 | 518 |
| 2013 | 550 |
| 2014 | 475 |
| 2015 | 1,361 |
| 2016 | 1,136 |
| 2017 | 1,867 |
| 2018 | 1,599 |
| 2019 | 1,157 |
| 2020 | 1,013 |
| 2021 | 405 |
| 2022 | 380 |
| 2023 | 525 |
| 2024 | 1,174 |
| 2025 | 556 |
| 2026 | 345 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tamiflu (Oseltamivir Phosphate)
2024 spending
$56K
Beneficiaries
528
593 claims
Per beneficiary
$107
$9.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $254,695 |
| 2021 | $34,177 |
| 2022 | $274,839 |
| 2023 | $67,191 |
| 2024 | $56,462 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials.
Gao Y, Guyatt G, Uyeki TM, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG, Sugaya N, Hirotsu N, et al. · N Engl J Med 2018 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis.
Gao Y, Zhao Y, Liu M, et al. · JAMA Intern Med 2025 · Network Meta-Analysis, Systematic Review
- Oseltamivir.
Bardsley-Elliot A, Noble S · Drugs 1999 · Clinical Trial, Controlled Clinical Trial
- Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis.
Zhao Y, Gao Y, Guyatt G, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials.
Malosh RE, Martin ET, Heikkinen T, et al. · Clin Infect Dis 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.